Older age, presence of multiple comorbidities, and longer length of hospital stay, rather than difference in glycaemic control, were associated with an increased risk of 1-year death following admission with severe hypoglycaemia in patients with diabetes, according to a Singapore study.
Adding continuous glucose monitoring (CGM) to conventional finger-prick test during pregnancy increases the time spent in the recommended glycaemic target range and improves neonatal health outcomes in patients with type 1 diabetes (T1D) compared with traditional test alone, according to the CONCEPTT* study presented at EASD 2017.
Dapagliflozin improves glycaemic control with sustained weight loss without an increased risk of diabetic ketoacidosis (DKA) in patients with type 1 diabetes (T1D) who are inadequately controlled with insulin, according to the DEPICT-1* study.
Once-weekly doses of the glucagon-like peptide-1 receptor agonist exenatide plus insulin glargine improved glucose control and weight loss in patients whose type 2 diabetes (T2D) was uncontrolled on basal insulin and metformin, according to findings from the DURATION-7* trial.
The novel, G-protein coupled receptor 119 (GPR119) agonist DS-8500a demonstrated dose-dependent glucose-lowering effects and favourable improvements in lipid parameters that extended up to 12 weeks in Japanese patients with type 2 diabetes mellitus (T2D), according to data presented at EASD 2017.
Individuals with type 2 diabetes (T2D) who were hospitalized with nonalcoholic fatty liver disease (NAFLD) had an elevated risk of cardiovascular disease (CVD), and death due to CVD, hepatocellular cancer, and other causes, according to a study presented at EASD 2017.
The incidence of cardiovascular (CV) events at 5 years was similar when adding sulphonylureas or pioglitazone to metformin in patients with type 2 diabetes (T2D) inadequately controlled with metformin alone, according to a head-to-head comparison in the TOSCA.IT* trial.
Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.
The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.